Connock, Martin; Hyde, Chris; Moore, David - In: PharmacoEconomics 29 (2011) 10, pp. 827-837
: sorafenib (Nexavar) for advanced hepatocellular carcinoma, and azacitidine (Vidaza) for higher-risk myelodysplastic syndromes … sorafenib models favoured log-Normal fits; however, since there is no statistical method for comparing AIC scores, and …